What is Clene Nanomedicine?
Clene Nanomedicine is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of innovative clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate, CNM-Au8, is currently under investigation in multiple clinical trials. These studies include a completed Phase 2 platform trial for amyotrophic lateral sclerosis (ALS), a completed Phase 2 proof of concept trial for early symptomatic ALS, and Phase 2 trials evaluating brain energy metabolites and the treatment of visual pathway deficits in multiple sclerosis. Additionally, Clene Nanomedicine is developing CNM-AgZn17, a gel polymer suspension for infectious diseases and wound healing, and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent for immune support and infection treatment. The company's focus on CSN therapeutics positions it at the forefront of nanomedicine innovation.
How much funding has Clene Nanomedicine raised?
Clene Nanomedicine has raised a total of $140.3M across 7 funding rounds:
Series A
$31.6M
Series B
$17M
Debt
$350K
Series D
$42.5M
Other Financing Round
$40M
Other Financing Round
$7.3M
Stock/Share Issuance
$1.5M
Series A (2015): $31.6M, investors not publicly disclosed
Series B (2016): $17M, investors not publicly disclosed
Debt (2020): $350K supported by PPP
Series D (2020): $42.5M featuring SymBiosis II
Other Financing Round (2023): $40M backed by Vivo Capital, Acuta Capital Partners, and Symbiosis Group
Other Financing Round (2024): $7.3M, investors not publicly disclosed
Stock/Share Issuance (2025): $1.5M, investors not publicly disclosed
Key Investors in Clene Nanomedicine
Vivo Capital
Vivo Capital, founded in 1996, is a global healthcare investment firm based in Palo Alto, California, with a focus on private and public equity, as well as venture capital. Their investment in Clene Nanomedicine suggests a strategic interest in the pharmaceutical and biotechnology sectors.
Acuta Capital Partners
Acuta Capital Partners is a California-based financial investment group specializing in healthcare-related investments. They support companies focused on research and innovation to improve health outcomes, indicating a potential alignment with Clene Nanomedicine's therapeutic development goals.
Symbiosis Group
Symbiosis Group is known for providing international open-access journal articles and scholarly publications in science. Their involvement, possibly through a related investment arm like SymBiosis II, suggests an interest in the scientific and research aspects of Clene Nanomedicine's work.
What's next for Clene Nanomedicine?
The recent major strategic investment in Clene Nanomedicine, amounting to $1.5M, is expected to accelerate the company's development pipeline and clinical trial progress. This capital infusion will likely support the advancement of CNM-Au8 through further clinical stages and potentially broaden its therapeutic applications. The company's commitment to developing novel nanotechnologies for challenging diseases suggests a strategic focus on unmet medical needs. Future growth will depend on successful clinical outcomes and regulatory approvals, with the company aiming to translate its scientific advancements into viable commercial products. The enterprise-level funding context indicates a strong belief in Clene Nanomedicine's long-term potential and its capacity to scale operations.
See full Clene Nanomedicine company page
